Cargando…

Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran

BACKGROUND: Hepatitis B infection is still the main cause of chronic liver disease in Iran, which is associated with significant economic and social costs. OBJECTIVES: This study aimed to estimate the financial burden caused by CHB infection and its complications in Iran. PATIENTS AND METHODS: Preva...

Descripción completa

Detalles Bibliográficos
Autores principales: Keshavarz, Khosro, Kebriaeezadeh, Abbas, Alavian, Seyed Moayed, Akbari Sari, Ali, Abedin Dorkoosh, Farid, Keshvari, Maryam, Malekhosseini, Seyed Ali, Nikeghbalian, Saman, Nikfar, Shekoufeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427913/
https://www.ncbi.nlm.nih.gov/pubmed/25977694
http://dx.doi.org/10.5812/hepatmon.15(4)2015.25854
_version_ 1782370798732836864
author Keshavarz, Khosro
Kebriaeezadeh, Abbas
Alavian, Seyed Moayed
Akbari Sari, Ali
Abedin Dorkoosh, Farid
Keshvari, Maryam
Malekhosseini, Seyed Ali
Nikeghbalian, Saman
Nikfar, Shekoufeh
author_facet Keshavarz, Khosro
Kebriaeezadeh, Abbas
Alavian, Seyed Moayed
Akbari Sari, Ali
Abedin Dorkoosh, Farid
Keshvari, Maryam
Malekhosseini, Seyed Ali
Nikeghbalian, Saman
Nikfar, Shekoufeh
author_sort Keshavarz, Khosro
collection PubMed
description BACKGROUND: Hepatitis B infection is still the main cause of chronic liver disease in Iran, which is associated with significant economic and social costs. OBJECTIVES: This study aimed to estimate the financial burden caused by CHB infection and its complications in Iran. PATIENTS AND METHODS: Prevalence-based and bottom-up approaches were used to collect the data. Data on direct medical costs were extracted from outpatient medical records in a referral gastroenterology and hepatology research center, inpatient medical records in several major hospitals in Tehran and Shiraz in 2013, and the self-reports of specialists. Data on direct non-medical and indirect costs were collected based on the patients’ self-reports through face-to-face interviews performed in the mentioned centers. To calculate the indirect costs, friction cost approach was used. To calculate the total cost-of-illness in Iran, the total cost per patient at each stage of the disease was estimated and multiplied by the total number of patients. RESULTS: The total annual cost for the activate population of CHB patients and for those receiving treatment at various disease stages were respectively 450 million and 226 million dollars, with 64% and 70% of which allocated to direct costs respectively, and 36% and 30% to indirect costs respectively. The total direct costs alone for each group were respectively 1.17% and 0.6% of the total health expenditure. Furthermore, the cost spent on drugs encompasses the largest proportion of the direct medical cost for all stages of the disease. CONCLUSIONS: According to the perspectives of payers, patients, and community, CHB infection can be considered as one of the diseases with a substantial economic burden; the disease, specifically in extreme cases, can be too expensive and costly for patients. Therefore, patients should be protected against more severe stages of the disease through proper treatment and early diagnosis.
format Online
Article
Text
id pubmed-4427913
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-44279132015-05-14 Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran Keshavarz, Khosro Kebriaeezadeh, Abbas Alavian, Seyed Moayed Akbari Sari, Ali Abedin Dorkoosh, Farid Keshvari, Maryam Malekhosseini, Seyed Ali Nikeghbalian, Saman Nikfar, Shekoufeh Hepat Mon Research Article BACKGROUND: Hepatitis B infection is still the main cause of chronic liver disease in Iran, which is associated with significant economic and social costs. OBJECTIVES: This study aimed to estimate the financial burden caused by CHB infection and its complications in Iran. PATIENTS AND METHODS: Prevalence-based and bottom-up approaches were used to collect the data. Data on direct medical costs were extracted from outpatient medical records in a referral gastroenterology and hepatology research center, inpatient medical records in several major hospitals in Tehran and Shiraz in 2013, and the self-reports of specialists. Data on direct non-medical and indirect costs were collected based on the patients’ self-reports through face-to-face interviews performed in the mentioned centers. To calculate the indirect costs, friction cost approach was used. To calculate the total cost-of-illness in Iran, the total cost per patient at each stage of the disease was estimated and multiplied by the total number of patients. RESULTS: The total annual cost for the activate population of CHB patients and for those receiving treatment at various disease stages were respectively 450 million and 226 million dollars, with 64% and 70% of which allocated to direct costs respectively, and 36% and 30% to indirect costs respectively. The total direct costs alone for each group were respectively 1.17% and 0.6% of the total health expenditure. Furthermore, the cost spent on drugs encompasses the largest proportion of the direct medical cost for all stages of the disease. CONCLUSIONS: According to the perspectives of payers, patients, and community, CHB infection can be considered as one of the diseases with a substantial economic burden; the disease, specifically in extreme cases, can be too expensive and costly for patients. Therefore, patients should be protected against more severe stages of the disease through proper treatment and early diagnosis. Kowsar 2015-04-25 /pmc/articles/PMC4427913/ /pubmed/25977694 http://dx.doi.org/10.5812/hepatmon.15(4)2015.25854 Text en Copyright © 2015, Kowsar Corp. http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
spellingShingle Research Article
Keshavarz, Khosro
Kebriaeezadeh, Abbas
Alavian, Seyed Moayed
Akbari Sari, Ali
Abedin Dorkoosh, Farid
Keshvari, Maryam
Malekhosseini, Seyed Ali
Nikeghbalian, Saman
Nikfar, Shekoufeh
Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran
title Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran
title_full Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran
title_fullStr Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran
title_full_unstemmed Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran
title_short Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran
title_sort economic burden of hepatitis b virus-related diseases: evidence from iran
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427913/
https://www.ncbi.nlm.nih.gov/pubmed/25977694
http://dx.doi.org/10.5812/hepatmon.15(4)2015.25854
work_keys_str_mv AT keshavarzkhosro economicburdenofhepatitisbvirusrelateddiseasesevidencefromiran
AT kebriaeezadehabbas economicburdenofhepatitisbvirusrelateddiseasesevidencefromiran
AT alavianseyedmoayed economicburdenofhepatitisbvirusrelateddiseasesevidencefromiran
AT akbarisariali economicburdenofhepatitisbvirusrelateddiseasesevidencefromiran
AT abedindorkooshfarid economicburdenofhepatitisbvirusrelateddiseasesevidencefromiran
AT keshvarimaryam economicburdenofhepatitisbvirusrelateddiseasesevidencefromiran
AT malekhosseiniseyedali economicburdenofhepatitisbvirusrelateddiseasesevidencefromiran
AT nikeghbaliansaman economicburdenofhepatitisbvirusrelateddiseasesevidencefromiran
AT nikfarshekoufeh economicburdenofhepatitisbvirusrelateddiseasesevidencefromiran